No abstract available.
Encephalomyelitis, Acute Disseminated*

No abstract available.
Animals ; Lordosis* ; Spine*

No abstract available.

Bile* ; Choledochal Cyst* ; Humans ; Infant* ; Peritonitis*

For more than 80% of body weight is transmitted through the anterior and middle column, the interbody gap produced by operative reduction of spondylolisthesis is potential risk factor for redisplacement, implant failure, pseudoarthrosis and kyphosis. In biomechanical aspect, augmentation of the anterior column support by interbody fusion is desirable to prevent above problems in surgical treatment of spondylolisthesis. Recently, circumferential fusion is recommended in high-grade spondylolisthesis (grade III, IV, or V ), but there is some controversy about additional interbody fusion in posterior instrumentation for low-grade spondylolisthesis (grade I or II ). So, the purpose of this retrospective study was to compare the segmental sagittal angle in 35 patients of low-grade spondylolisthesis who was performed posterior instrumentation with or without posterial lumbar interbody fusion (PLIF) and to find out the risk factors of the loss of segmental sagittal angle in cases of posterior instrumentation without posterial lumbar interbody fusion (PLIF).
Body Weight ; Humans ; Kyphosis ; Pseudarthrosis ; Retrospective Studies ; Risk Factors ; Spondylolisthesis*

No abstract available.
Arthroplasty, Replacement, Hip*

No abstract available.

PURPOSE: The purpose of this study was to analyze clinical and radiological results after debridement arthroplasty during primary elbow arthroplasty. MATERIALS AND METHODS: This study involved 25 primary elbow osteoarthritis cases that were treated by debridement arthroplasty from January 1996 to December 2004 with at least a 2 year follow up (mean: 41.3 months). Mean patient age was 45.5 years. Clinical outcomes were analyzed using preoperative and postoperative ranges of motion, Mayo Elbow Performance Scores (MEPS), and Visual Analogue Scale scores. Radiologic analysis was based on plain radiographs. RESULTS: Average flexion-extension arc improved from 72degrees ROM preoperatively to 110.5degrees postoperatively (p<0.001). Mean MEPS was 89.5 points preoperatively and increased postoperatively (p<0.05). Humeral fenestration size decreased from 27% to 20.5%. Bony spurs of the olecranon and coronoid process recurred in 8 cases. Postoperative LOM was found to be associated with spur recurrence (p<0.05). CONCLUSION: Debridement arthroplasty may be recommendable for primary elbow osteoarthritis as it reduces pain and improves functional outcomes, including range of motion. Spur recurrence was found to be associated with a reduced range of motion.
Arthroplasty ; Debridement ; Elbow ; Follow-Up Studies ; Humans ; Olecranon Process ; Osteoarthritis ; Range of Motion, Articular ; Recurrence

PURPOSE: Recombinant human growth hormone is an effective therapy for short-statured children born small for their gestational age (SGA). This single-arm, multicenter, phase III clinical study of such children was designed to assess the efficacy and safety of treating them with recombinant human-growth-hormone (Eutropin(TM) Inj.) for 6 months. METHODS: Between 2005 and 2007, 30 treatment naive, prepubertal, short-statured SGA-born children were recruited as participants. Eutropin(TM) Inj. was administered for 6 months with a subcutaneous dose of 0.48 mg/kg/wk. The primary endpoint was the change in height velocity from the baseline to month 6. Various parameters were checked to obtain secondary outcome measures and to meet safety criteria. RESULTS: Height velocity significantly increased from 5.36 +/- 1.59 cm/yr at baseline to 10.66 +/- 2.03 cm/yr at month 6 (P < 0.0001). Secondary outcome measures (height velocity at month 3, height SDS for chronological age (CA), weight SDS for CA, bone maturation, and IGF-I and IGFBP-3 levels) were also significantly increased. Eutropin(TM) Inj. was well tolerated and safe over 6 months of treatment. CONCLUSION: The clinical efficacy and safety of Eutropin(TM) Inj. was demonstrated for the 6 month treatment of prepubertal children with short stature due to SGA. Further long-term study is needed.
Child ; Gestational Age ; Human Growth Hormone ; Humans ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor I ; Outcome Assessment (Health Care)

No abstract available.
Reference Values* ; Technetium Tc 99m Exametazime* ; Tomography, Emission-Computed, Single-Photon*